Showing results (341-350 of 534) with videos related to

Sort By:
Pageof 54
American Journal of Hematology|August 28, 2024
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemiaWei-Ying Jen, Elias Jabbour, Nicholas J Short, et al.
Leukemia|October 19, 2022
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysisNicholas J Short, Chenqi Fu, Donald A Berry, et al.
JAMA Oncology|October 8, 2020
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysisNicholas J Short, Shouhao Zhou, Chenqi Fu, et al.
American Journal of Hematology|October 10, 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsIman Abou Dalle, Hagop M Kantarjian, Nicholas J Short, et al.
Haematologica|March 26, 2026
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemiaDaniel Nguyen, Elias Jabbour, Hagop M Kantarjian, et al.
Iscience|July 23, 2026
Maternal biological aging from pregnancy through four years postpartum with disrupted recovery by subsequent pregnancyLaura Etzel, Patricia Garrett-Peters, Qiaofeng Ye, et al.
British Journal of Haematology|April 11, 2024
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expressionWei-Ying Jen, Koji Sasaki, Sanam Loghavi, et al.
Frontiers in Oncology|November 16, 2020
Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood Advances|February 6, 2026
Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow CytometryShaoying Li, Nicholas J Short, Wei Wang, et al.
Pageof 54